Book Chapter10.1007/978-3-031-49068-2_29
An Overview of Personalized Medicine Development Through Recent Advances in Genome-Wide Association Studies
Dženita Omerkić Dautović,Adna Ašić +1 more
- 01 Jan 2024
- pp 261-274
TL;DR: Genome-wide association studies enable personalized medicine development through tailored therapy based on individual genetic makeup and clinical parameters.
read more
Abstract: Genome-wide association studies, a term often in use following completion of The Human Genome Project, refers to the analysis and comprehensive understanding of human genetic landscape for practical purposes. An example of such application would be the development of personalized medicine approach and subsequent abandonment of the "one-size-fits all" model. In personalized medicine, a patient's therapy is tailored according to their indication, clinical parameters, genotype and environmental effects in order to enable the best possible therapeutic outcome with as few adverse side effects, as possible. This review is about a series of exciting events that were important for the development of personalized medicine and to introduce the most important genome-wide association studies analysis approaches that made this possible, such as next-generation sequencing platforms and biomarker identification. In addition, we are presenting several examples of how personalized medicine improved our understanding of adverse drug reactions and ways to optimize patient's therapy to their best interest.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
References
Insurance coverage policies for personalized medicine.
Andrew M. Hresko,Susanne B. Haga +1 more
TL;DR: This analysis highlights the variability of coverage determinations and factors considered, suggesting that the adoption of personal medicine will be affected by numerous factors, but will continue to be slowed due to lack of demonstrated clinical benefit.
90
Clinical Application of CYP2C19 Pharmacogenetics Toward More Personalized Medicine.
TL;DR: Up-to-date knowledge on functional CYP2C19 variants discovered in phenotyped humans studied at the molecular level in vitro is summarized.
Criteria for Scientific Evaluation of Novel Markers: A Perspective
TL;DR: I elaborate on various aspects of this guideline, extend it to other types of markers and other clinical domains, and add various recommendations to further guide researchers, practicing physicians and laboratory workers involved in the study, application, or measurement of markers.
74
Artificial Intelligence, Big Data and Machine Learning Approaches in Precision Medicine & Drug Discovery.
Anuraj Nayarisseri,Ravina Khandelwal,Poonam Tanwar,Maddala Madhavi,Diksha Sharma,Garima Thakur,Alejandro Speck-Planche,Sanjeev Kumar Singh +7 more
TL;DR: In this article, an overview of machine learning-based tools for drug discovery is presented, including support vector machine (SVM), random forest (RF), decision tree and Artificial Neural Network (ANN), which can be employed in SNP discoveries, drug repurposing, ligand-based drug design, LBDD, LBVS and Structure-based Virtual Screening.
73
Pharmacogenomic and pharmacogenetic-guided therapy as a tool in precision medicine: current state and factors impacting acceptance by stakeholders.
TL;DR: Pharmacogenetic/pharmacogenomic testing is currently available for a wide range of health problems including cardiovascular disease, cancer, diabetes, autoimmune disorders, mental health disorders and infectious diseases, and several issues that will affect adoption of PGx testing in the United States (US) over the next few years are reviewed.